Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
|ClinicalTrials.gov Identifier: NCT00037622|
Recruitment Status : Terminated (Safety concerns from other studies.)
First Posted : May 20, 2002
Last Update Posted : August 19, 2009
Information provided by:
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.
|Condition or disease||Intervention/treatment|
|Chronic Hepatitis B||Drug: ACH-126, 443 (beta-L-Fd4C)|
Evaluation of safety and antiviral activity of the 5mg dose of ACH-126,443 for up to three months of treatment in the population described.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Treatment Protocol to Provide Continued ACH-126,443 to Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection|
|Study Completion Date :||May 2003|
No Contacts or Locations Provided